Appointment of Nomura-Code as Joint-Broker
Medgenics (LSE: MEDG, MEDU), the company that is developing a novel approach to the manufacture and delivery of therapeutic proteins continuously in patients using their own tissue, is proud to announce today the appointment of Nomura Code Securities as joint-broker to the Company with SVS Securities plc with immediate effect.
Commenting on the new appointment Dr. Andrew Pearlman, CEO of Medgenics said: "We are delighted by this new appointment and believe that the combination of Nomura Code Securities, with acknowledged expertise in the life sciences space and its reputation amongst institutional investors, and SVS Securities plc, with its small cap investor expertise, greatly strengthens Medgenics broking team to support the Company going forward"
For further information, please contact:
Andrew Pearlman + 972 4 902 8900
CEO, Medgenics, Inc
Mike Wort / Anna Dunphy + 44 207 861 3838
De Facto Communications
Jonathan Senior +44 207 776 1219
Ian Callaway / Alex Mattey +44 207 638 5600
James Pinner / Derek Crowhurst +44 207 444 0800
Religare Capital Markets (Nomad)
This information is provided by RNS